But has the correct dose been chosen for phase 3 trials of this agent, which is one of several possible replacements for warfarin in development? (Agnelli G et al. <i>Circulation</i>; published ...

In the fall of 2018, the 2.5-mg dose of the name-brand rivaroxaban was introduced to the U.S., when it was approved for prevention of major adverse cardiovascular events in CAD and PAD.

However, compared with aspirin, rivaroxaban was associated with higher rates of major bleeding (risk difference, 0.9 percentage points; 95% CI, –0.1 to 3.7) and intracranial hemorrhage (risk ...

A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose aspirin revealed a link between rivaroxaban and higher rates of major bleeding and ...